That’s a wrap for #ASCO26 💕
We are excited to dive in to our key takeaways in next week’s episode including some of the plenary sessions (#RASolute ‼️#SARC1, #PROTREUS) & more
📅 & save the date for our #ASH26 free heme board review session for trainees Dec 11🩸 @OncBrothers
More @ASCO news coverage of the SARC041 study of abemaciclib versus placebo in DDLPS. Median PFS of 9.7 months vs. 1.5 months. The efficacy of abemaciclib looks remarkable and we are looking forward to future studies in #liposarcoma#asco26#sarcoma
Standing ovation for a ***breakthrough*** in #pancreaticcancer 🥹🥹🥹
#RASolute today presented at #ASCO26:
Daraxonrasib DOUBLES the median overall survival in metastatic pancreatic cancer w/ +w/o RAS (mOS 13.2 mo vs. 6.6 mo)
A HUGE advance in one of the most lethal cancers 💜
Exciting day! Two opportunities to hear the results of our survey on AI use in HO fellowship training.
#1 - Oncology 2.0: How Artificial Intelligence Is Closing the Information GapOr Is It?
📍Room S102
🕑9:45 - 11:15 AM
#AI#ASCO26
PODCAST-HOF trial featuring @TheFellowOnCall and @TwoOncDocs and published in @JCO_ASCO-OP being highlighted as one of the biggest med ed research studies of the past year to know at the #ASCO26 Medical Education Committee on Practice event! 🎉
The most inspirational part of the @SARCtrials semiannual meeting was hearing AYA OST survivors share their stories and hopes for the future.
Thank you to @AgentsMIB for amplifying their voices and inspiring us all.
Advocacy leads to policy change 🎗️
Huge THANK YOU to everyone who joined our “Clinicals to Exam” board review session! 📚🔥🎙️
Nothing beats meeting fellow learners IRL 🫶
Shoutout to our incredible co-hosts @OncBrothers and amazing panelists @JenSchwartzIUSM and Dr. Carlos Doti 👏✨
Now…who’s ready for #ASCO26
1 day until Clinicals to Exam 🌟 pre #ASCO26
From 1-5PM, we will cover a high yield overview of:
Board Prep 101
Breast CA
Lung CA
CRC
Pancreatic CA
Testicular CA
Prostate CA
Genetics & Biomarkers
& new this year a special panel Life After Fellowship inc @JenSchwartzIUSM
🌟3🌟 part Pancreatic Cancer updates with our very special guest @MPishvaian from @TumorBoardTues 💜
Part 1: risk factors, germline & somatic testing, diagnosis & localized tx - out this week!
Part 2: tx paradigm for metastatic pancreatic CA
Part 3: supportive care & trials
We did a new topic this week!
Rad Onc 101 with @RadOncTalks ☢️
In part 1, we reviewed types of RT, how it works, the patient experience & common AEs
In part 2 we will review duration & fractionation schemes, indications for RT & more
@HemOncFellows
CONGRATS to all of those who matched into the best speciality this past week!!
& congrats to all who found out they passed their Onc Boards today, we love hearing from you ❤️
We are back this week with updates on GISTs & next week from #ASH25
https://t.co/tpfkleEJHd
#desmoid has a sustained impact on pts lives
‼️at 10yr of disease only half remain at full time job
‼️ ONLY 17% received counseling by reproductive specialists
‼️Desmoid pts are often excluded from supportive programs reserved for cancer survivors
#ctos25
When I started in #sarcoma, Brian welcomed me into the community. He once told me, when I become senior, to extend that same generosity & support to the next physician who joined our field. That was Brian, always lifting others up & inspiring us all to advance sarcoma together.
Congrats to all fellows who took boards last week!
This week we covered some updates from #ESMO25 in urothelial CA:
-#POTOMAC in NMIBC
-#KN905 & #IMvigor011 in MIBC
-#FORAGER1 & DV + Toripalamab in muC
Coming up, will update Anal CA, Hodgkin Lymphoma topics & job search tips!
This week we released 2025 updates on soft tissue #sarcoma with our local sarcoma expert @SamArmstrongMD
Which of the following is a preferred approved treatment since 2023 for unresectable desmoid tumors?
@HemOncFellows